VG081821AC

N/A

Report date: 2026/04/13 20:02:18
NME

Base Information

Drug NameVG081821AC
Drug Alias NameVG081821ACVG-081821AC
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdenosine A2a receptor antagonists
TargetsAdenosine A2a receptor
Therapy Area/IndicationsParkinson DiseaseMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesZhejiang Vimgreen Pharmaceuticals Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesZhejiang Vimgreen Pharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsParkinson DiseaseMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A